Search Immortality Topics:

Page 11234..1020..»


Category Archives: Biotechnology

iecam to found a global joint venture with biotechnology company 7CBasalia – Glass on Web

A global player in glass and chemicals, iecam announced plans to invest in Basalia Technology, a groundbreaking solution in the green and circular economy space and a significant Turkish innovation in bioeconomics. This decision marks iecam's first-ever investment in biotechnology. iecam signed a memorandum of understanding to found a global joint venture with 7CBasalia, the owner of Basalia Technology which was developed to make the world more sustainable.

Upon establishment of the global enterprise set forth in the protocol under the iecam-7CBasalia partnership, iecam will further test the innovative technology, which has already registered positive results, first in its own facilities as part of a pilot project. After evaluating the outputs of this testing effort, iecam will ensure that 7CBasalia's circular business model which turns waste into added value products reaches across the globe.

iecam's Chairman of the Board of Directors Prof. Dr. Ahmet Krman stated the following: "We saw that Basalia Technology yielded positive results in our initial testing. We believe that this solution will mark a revolutionary breakthrough in the emerging field of bioeconomics. We signed a memorandum of understanding with 7CBasalia, a biotech start-up, to found a global joint venture in order to help develop and disseminate this technology globally. iecam will bolster R&D efforts in this key area with its investment in Basalia Technology, a solution that recycles all sorts of wastes and turns them into harmless substances and value-added products. In addition, we will significantly contribute to the international dissemination of this technology, which closely aligns with our sustainability goals, after implementing it as a pilot project at iecam and seeing its results on a larger scale. Having production activities in 14 countries and reaching 150 countries with its value-added products, iecam is the point of origin and the global representative for the Turkish glass industry. Note that glass is the worlds most sustainable material. iecam, with its new investment will play an active role in the global distribution of Basalia Technology, which we believe will give a huge boost to sustainability.

Ahmet Baal, the inventor of Basalia Technology and one of the founders of 7CBasalia, added: "This innovative system stops wastes from being an environmental problem and turns them into eco-friendly value-added products. Thanks to Basalia Technology, wastewater is rendered reusable, while solid waste that is combined with organic waste is first made harmless. The next step is the generation of hydrogen, an eco-friendly source of energy. Basalia provides solutions to companies that face waste problems while also working in conjunction with city and national governments to develop Green City projects. As a leader of corporate R&D operations in Turkey, iecam will play a major role in the further development of this innovative solution with its strong know-how and advanced capabilities in technology development. I am certain that this unprecedented innovation will rapidly spread across the world, with the assistance of the expansive global footprint of iecam, which has production operations in 14 countries worldwide and reaches 150 countries with its products."

A global setter in the glass and chemicals industries, iecam announced plans to invest in Basalia Technology, an innovative solution developed to ensure a sustainable world. iecam signed a memorandum of understanding with 7CBasalia, owner of Basalia Technology and an enterprise focused on the green and circular economy. With the investment in this technology that is developed for turning all types of waste into harmless materials, iecam and 7CBasalia will support R&D efforts in this emerging field.

iecam considers this technology as a game-changing solution. Successful results were recorded in initial testing following a pilot project in iecams facilities. As a result, iecam will support dissemination of Basalia Technology across all its international platforms worldwide. This investment will mark the first-ever biotechnology investment of iecam, which operates in nine business lines across Turkey.

7CBasalia, founded in Turkey in 2020, holds patents for Basalia Technology, a groundbreaking solution that features an innovative system inherently different from conventional technologies. The system is designed to stop wastes from being an environmental problem by turning them into eco-friendly value-added products. Contamination of the natural environment by wastewater is currently one of the biggest problems facing the world today.

However, Basalia Technology turns wastewater into distilled water. As a result of this process, wastewater is recovered as a resource that can be reused. The revolutionary system also serves as a critical solution to the solid waste problem. First, solid waste that is combined with organic waste is rendered harmless. Then, the system generates hydrogen an eco-friendly source of energy. 7CBasalia works in cooperation with international organizations on issues related to climate change, the environment, and sustainability to deliver solutions for companies that face waste-related problems. In addition, 7CBasalia partners with city and national governments to create Green City solutions.

Prof. Dr. Ahmet Krman, iecam's Chairman of the Board of Directors, announced and remarked on the new investment decision: "Throughout its 86-year history, iecam has remained committed to respecting people and the environment. From the beginning, iecam has offered solutions for a more sustainable world with its value-added products developed via its robust R&D infrastructure. More recently, we have been evaluating new investment areas that support our strong growth objectives. iecam recognized the remarkable harmony between 7CBasalias innovative circular biotechnology and Green Cities vision and its own sustainability-oriented development goals. We signed a global partnership MOU to turn this harmony into synergy and to support the global distribution of Basalia Technology. We firmly believe in this revolutionary technologys benefits and its development potential following our preliminary trials. Having production operations in 14 countries and reaching 150 countries with its value-added products, iecam is the point of origin and the global representative for the Turkish glass industry. Note that glass is the most sustainable material in the world. With this new investment, iecam will implement Basalia Technology. We believe this groundbreaking innovation will make a positive contribution to our planet which is facing ever-growing risks from climate change. First, iecam plans to deploy the technology at its own facilities for additional testing. Based on the results of our internal implementation, we will play an active role in distributing Basalia Technology globally. iecam keeps sustainability at the center of all its business processes from raw material to end product. We are committed to making value-generating investments for the benefit of our planet as well as each and every stakeholder."

Mr. Krman continued: "iecam is currently the worlds second largest glassware producer in terms of production capacity. We also rank among the top five manufacturers of flat glass and glass packaging worldwide. In addition to being the eighth largest producer of soda ash globally, we are the world leader in chromium chemicals. As we move ahead toward our goal of positioning iecam Group as one of the top three producers in its core business areas, we are proud to represent our home country across a wide geography. iecam focuses on ensuring that the value it creates in all its activities can deliver a better future. Our Care for Next sustainability strategy embodies iecams approach to sustainability. With each investment we make, every innovative technology that we develop, and every stakeholder that we empower, we further embrace sustainability. As a groundbreaking innovation that we have great faith in, our latest investment in Basalia Technology is a clear demonstration of our compherensive and inclusive sustainability approach."

Ahmet Baal is the inventor of Basalia Technology and one of the founders of 7CBasalia. He elaborated on the launch of the innovative technology following many years of extensive R&D efforts and on the new joint venture to be established with iecam: Warning signals linked to global climate change have started to appear through the growing number of natural disasters that have occurred around the world. We started to work intensively on green and circular technologies that would respond to these impending threats and that would present a value-added solution to the waste issue. Upon completing the development process of Basalia Technology that we have worked on for many years, we became ready to make it available for widespread use across the world. In 2020, we founded 7CBasalia. Capable of capturing and bonding carbon and other contaminators in combustion gas, our revolutionary system offers significant benefits, such as generating hydrogen from all organic and inorganic waste. Basalia Technology consists of next-generation microorganism groups and physico-chemical systems that are evolved under extreme conditions and that function in synergy with one another. The technology that we developed can be used in areas such as waste disposal, precious material recovery from waste, deionized water generation, production of environmentally-friendly isolation materials, and organic land grading generation. Our system is much more effective, efficient, sustainable, and affordable compared to alternative bio-remediation systems. Basalia Technology is designed to be a holistic and bio-cycle solution that addresses global warming and chemical waste issues, which rank among the most pressing long-term problems facing the world today. I believe that iecam, one of the pioneers of corporate R&D operations in Turkey, will play a significant role in further development of this effort with its strong know-how and capabilities in technology development. Engaging in production activities in 14 countries and reaching consumers in 150 countries worldwide, iecam will assume a pioneering role in leveraging Basalia Technology on a much larger scale. We are tremendously delighted to have the support and confidence of iecam, the founder of the glass industry in Turkey, and the countrys global representative in glass and chemicals. I am certain that this game-changing innovation will spread around the world at a well-deserved speed thanks to iecam's extensive global footprint."

Read the rest here:
iecam to found a global joint venture with biotechnology company 7CBasalia - Glass on Web

Posted in Biotechnology | Comments Off on iecam to found a global joint venture with biotechnology company 7CBasalia – Glass on Web

GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer – BioSpace

BOSTON--(BUSINESS WIRE)-- GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward Tad Stewart, who joins the team as Chief Business Officer (CBO).

Mr. Stewart has worked extensively in business and corporate development in the biotechnology and pharmaceutical space for more than 20 years. He has played an integral strategic role in scaling platform biotechnology companies from early stages through FDA-approval and product launch. Mr. Stewart served most recently as Chief Business Officer of Ribon Therapeutics. Prior to his role at Ribon he served as President and CEO of Commense, Inc., Chief Business Officer of Crescendo Biologics, and spent many years with Merrimack Pharmaceuticals in various roles, including SVP of Business Development and Head of Commercial. Mr. Stewart received his MBA from Cornell University.

We are thrilled to have Tad join our executive team. His deep experience in business development and transactions will be instrumental to our partnering activities, and his expertise in product development will accelerate our commercialization efforts, said Daniel J. Mandell, PhD, Co-Founder and Chief Executive Officer of GRO Biosciences. Tad is an established leader in biotechnology, and his unique combination of transactional and strategic savvy will be a great asset to GRObio as we continue to advance our platform and pipeline.

About GRO Biosciences

GRO Biosciences (GRObio) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Companys NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by George Church, PhD of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005427/en/

See more here:
GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer - BioSpace

Posted in Biotechnology | Comments Off on GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer – BioSpace

Polymerase Chain Reaction (PCR) Market to Expand by 3.3x as Application in Pharmaceutical & Biotechnology Industry Grows – BioSpace

Polymerase Chain Reaction (PCR) Sales to Surpass US$ 12 Bn through 2031 as Adoption of Real-Time PCR Surges amid COVID-19

Fact.MRs latest study discusses factors affecting the polymerase chain reaction (PCR) market growth. It provides in-depth analysis of various market segments, including product and end user across seven major regions. The report further profiles leading PCR manufacturers and examines the effect of their growth strategies on the global market.

Fact.MR A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global polymerase chain reaction (PCR) market will reach US$ 3.6 Bn by the end of 2021. Owing to the surging demand for PCR products, the overall market is projected to register growth at 10% CAGR between 2021 and 2031.

Sales in the PCR market are expected to increase with rising prevalence of target diseases and genetic disorders. Also, factors such as growing popularity of portable PCR testing kits, advancements in PCR technology, and increasing government funding for research activities will facilitate the growth in the market.

PCR has emerged as an ideal technique for the amplification of DNA sequences. It is a simple and cost-effective technique which produces results rapidly. It is an extensively used technique in medical laboratory research for a wide range of applications including biomedical research and criminal forensics.

The unprecedented outbreak of COVID-19 had a positive impact on the PCR market. It created huge demand for reliable and rapid detection techniques such as RT-PCR. Various companies also launched novel PCR test kits for the detection of virus.

Also, RT-PCR emerged as an ideal technique for detection of COVID-19 virus. It is significantly faster and has lower risk of contamination or errors.

Request a report sample to gain compressive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4861

As per Fact.MR analysis, PCR reagents will account for around 60% of total PCR market revenue by 2031. Rising demand for diagnostic tests and launch of new reagents specific to the test type are some key factors accelerating the demand for reagents used in polymerase chain reaction. Furthermore, RT PCR systems market to witness significant growth.

Regionally, North America will continue to dominate the PCR market, owing to the presence of a well-established healthcare infrastructure, continuous advances in clinical research, and high prevalence of genetic disorders such as Klinefelter's syndrome and Down syndrome. The region is poised to expand at a healthy growth rate of 7.5% annually.

However, Asia is projected to register the fastest growth on the back of increasing penetration of PCR products, rising government support, high prevalence of chronic diseases, and expanding healthcare infrastructure.

As the demand for PCR continues to rise, leading manufacturers are moving towards developing portable micro-scale devices. They also are introducing advanced PCR instruments, reagents and consumable that will allow quick nucleic acid amplification. This is expected to create growth opportunities for the market, says a Fact.MR analyst

Key Takeaways from Polymerase Chain Reaction Market Survey

Key Drivers

Key Restraints

To gain in-depth insights on Polymerase Chain Reaction Market, request methodology at

https://www.factmr.com/connectus/sample?flag=RM&rep_id=4861

Competitive Landscape

Key players operating in the polymerase chain reaction market are embracing advanced technologies for the development of new products. They have adopted various strategies such as mergers, partnerships, collaborations and manufacturing of advanced portable PCR products to increase their sales.

Some of the prominent players operating in the polymerase chain reaction market profiled by Fact.MR are:

More Insights on the Global Polymerase Chain Reaction Sales Outlook

Fact.MR provides an incisive coverage on global polymerase chain reaction market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for polymerase chain reaction with a detailed segmentation on the basis of:

Key Questions Covered in the Polymerase Chain Reaction Market Outlook Report

Explore Fact.MRs Coverage on the Healthcare Domain

Rapid Medical Diagnostic Kits Market- Infectious disease incidence has been steadily increasing over the last few decades, driving up demand for rapid medical diagnostic kits around the world. The need to detect novel pathogens that cause diseases is propelling the market forward. The low cost of rapid medical diagnostic kits is propelling market growth. Blood glucose testing is in high demand, and it has been growing at the quickest rate of all types of tests across all geographies. Technology advancements and strategic alliances by key market players have paved the way for rapid medical diagnostic kit innovations.

COVID-19 Saliva-based Detection Kits- COVID-19 detection treatments are likely to be in high demand due to the availability of COVID-19 virus variants and the continued danger of infection. Manufacturers are focusing on delivering cost-effective and convenient testing solutions as COVID-19 diagnostics become more widely employed. While vaccination initiatives have reduced the incidence rate in some nations, the virus continues to represent a serious concern and has a high occurrence rate due to mutant forms. Future viral mutant strains, as well as increased knowledge of COVID-19 testing, are predicted to maintain market growth.

PCR and Real-time PCR Molecular Diagnostics Market - The COVID-19 pandemic has boosted prospects for the growth of the PCR and real-time PCR molecular diagnostics market. Real-time (qPCR) and digital (dPCR) PCR tests have been used in a variety of healthcare settings to detect and diagnose potential cases. Because of its high sensitivity, healthcare providers have embraced PCR tests on a large scale. As a result of such trends, the global PCR and real-time PCR molecular diagnostics market is poised to soar to new heights, surpassing a significant revenue threshold in the coming decade.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.

MarketNgage is powered by Fact.MR our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.

You can access all our healthcare research reports by signing up with MarketNgagesMarket Research Subscriptionwith FREE credits. MarketNgage is powered by Fact.MR A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.

Contact:

Mahendra SinghUS Sales Office11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E: sales@factmr.com

Source: Fact.MR

Go here to read the rest:
Polymerase Chain Reaction (PCR) Market to Expand by 3.3x as Application in Pharmaceutical & Biotechnology Industry Grows - BioSpace

Posted in Biotechnology | Comments Off on Polymerase Chain Reaction (PCR) Market to Expand by 3.3x as Application in Pharmaceutical & Biotechnology Industry Grows – BioSpace

Illumina Named to 2021 Dow Jones Sustainability Indices With Highest Score in Pharmaceuticals, Biotechnology and Life Sciences Industry – Yahoo…

Northampton, MA --News Direct-- Illumina

Were honored to be named to the prestigious 2021 Dow Jones Sustainability Indices for a third year in a row. Illumina received the highest score in the Pharmaceuticals, Biotechnology and Life Sciences industry.

Inclusion in the DJSI highlights our commitment to continuously improving and growing our Corporate Social Responsibility (CSR) program to build a more sustainable and equitable future for all. Our program focuses on accelerating access to genomics, supporting our communities, and integrating environmental stewardship into our operations.

If you would like to hear more about our CSR program, join us at our inaugural ESG Investor event on Tuesday Nov 16 at 11 am PT.

Thank you to all our employees for championing the needs of patients, customers, our communities, and our planet.

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/illumina-named-to-2021-dow-jones-sustainability-indices-with-highest-score-in-pharmaceuticals-biotechnology-and-life-sciences-industry-107725996

See more here:
Illumina Named to 2021 Dow Jones Sustainability Indices With Highest Score in Pharmaceuticals, Biotechnology and Life Sciences Industry - Yahoo...

Posted in Biotechnology | Comments Off on Illumina Named to 2021 Dow Jones Sustainability Indices With Highest Score in Pharmaceuticals, Biotechnology and Life Sciences Industry – Yahoo…

Food Biotechnology Market 2021 Detailed Analysis of top Ventures with Regional Outlook | Key Companies: ABS Global, Arcadia Biosciences, AquaBounty…

The report on Global Food Biotechnology Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition of the product or service studied in the report. Along with this, it also contains a summary of the main applications of this product or service in various industrial sectors. In addition, market research experts have also provided information on the manufacture or production of the product or service and its distribution strategy.

Other important factors studied in the global Food Biotechnology market report include demand and supply dynamics, industrial processes, import and export scenarios, R&D development activities and cost structures. In addition, this report also calculates figures for demand and supply for consumption, production cost, gross profit margins and sales price for products.

Get FREE Sample copy of this Report with Graphs and Charts at:https://reportsglobe.com/download-sample/?rid=289972

The segmentation chapters enable readers to understand aspects of the market such as its products, available technology and applications. These chapters are written to describe their development over the years and the course they are likely to take in the coming years. The research report also provides detailed information on new trends that may define the development of these segments in the coming years.

Food Biotechnology Market Segmentation:

Food Biotechnology Market, By Application (2016-2027)

Food Biotechnology Market, By Product (2016-2027)

Major Players Operating in the Food Biotechnology Market:

Company Profiles This is a very important section of the report that contains accurate and detailed profiles for the major players in the global Food Biotechnology market. It provides information on the main business, markets, gross margin, revenue, price, production and other factors that define the market development of the players studied in the Food Biotechnology market report.

Global Food Biotechnology Market: Regional Segments

The different section on regional segmentation gives the regional aspects of the worldwide Food Biotechnology market. This chapter describes the regulatory structure that is likely to impact the complete market. It highlights the political landscape in the market and predicts its influence on the Food Biotechnology market globally.

Get up to 50% discount on this report at:https://reportsglobe.com/ask-for-discount/?rid=289972

The Study Objectives are:

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Food Biotechnology market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Some Major Points from Table of Contents:

Chapter 1. Research Methodology & Data Sources

Chapter 2. Executive Summary

Chapter 3. Food Biotechnology Market: Industry Analysis

Chapter 4. Food Biotechnology Market: Product Insights

Chapter 5. Food Biotechnology Market: Application Insights

Chapter 6. Food Biotechnology Market: Regional Insights

Chapter 7. Food Biotechnology Market: Competitive Landscape

Ask your queries regarding customization at: https://reportsglobe.com/need-customization/?rid=289972

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

Link:
Food Biotechnology Market 2021 Detailed Analysis of top Ventures with Regional Outlook | Key Companies: ABS Global, Arcadia Biosciences, AquaBounty...

Posted in Biotechnology | Comments Off on Food Biotechnology Market 2021 Detailed Analysis of top Ventures with Regional Outlook | Key Companies: ABS Global, Arcadia Biosciences, AquaBounty…

Qiutang Li, Neurophth CSO, Named Top 25 Women Leaders in Biotechnology 2021 – KWCH

Published: Oct. 25, 2021 at 8:30 AM CDT|Updated: 16 hours ago

SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Neurophth Therapeutics Ltd.,("Neurophth") a fully-integrated genomic medicines company seekingto improve lives through the curative potential ofgene therapies, today announced that Qiutang Li, Ph. D., Neurophth's Chief Scientific Officer, has been listed as one of The Top 25 Women Leaders in Biotechnology of 2021 by The Healthcare Technology Report.

Neurophth congratulates its very own Dr. Qiutang Li as well as all the other award winners who have been recognized by The Healthcare Technology Report in their Top 25 Women Leaders in Biotechnology 2021. According to The Healthcare Technology Report, theseaccomplished women were selected based on hundreds of nominations and comprehensive analysis of professional milestones achieved, longevity in the biotech field and demonstrated domain expertise. They represent a diverse range of positions, specialties, and backgrounds.Formore information on The Healthcare Technology Report, please visit the official website at https://thehealthcaretechnologyreport.com/the-top-25-women-leaders-in-biotechnology-of-2021/.

"I amhumbled andhonoredto be included among this list of outstanding women leaders who are boldly changing the future of life science industry, " saidDr. Qiutang Li. "I share this distinction with all my Neurophth femalecolleagueswho come to work each day to share their expertise and insights as we follow the company'svision of 'buildinga brighter future for patients withinnovative gene therapies'and looking forward to leadtheteam into the successful development of the first China-manufactured AAV ocular gene therapy product globally."

"Congratulations to these exceptional women whose passion for creating medicines of value have led them to consistently achieve and thrive in our ever-evolving life sciences industry," said Dr. Alvin Luk, CEO of Neurophth. "Qiutang, a Chinese female scientist named Top 25 women leaders in Biotechnology of 2021, is an outstanding scientific leader who is leading all R&D efforts in both China and USA to take Neurophth's first product, NR082 for the treatment of ND4-mutated Leber hereditary optic neuropathy, from IND-enabling studies to clinical trial. She also works tirelessly to expand our portfolio pipeline from ocular to extra-ocular diseases".

Dr. Qiutang Li has over 30 years of experience in basic and applied biomedical research with extensive knowledge in gene therapy for hepatic deficiencies, ocular diseases, and viral vector reconstruction. She joins Neurophth from the University of Louisville School of Medicine, where she was a tenured professor in the Department of Ophthalmology and Visual Sciences for over 14 years. Throughout her career, Dr. Li has published more than 45 publications in peer-reviewed journals including IOVS, PNAS, Nature Review Immunology, and Science. Dr. Li earned both of her bachelor and master's degrees in Genetics from Peking University, China, and her doctoral degree in Molecular Cell Biology from Washington University, St. Louis.

About Neurophth

Neurophth is China's first gene therapy company for ophthalmic diseases. With subsidiaries in China (Wuhan, Shanghai and Suzhou) and US (San Diego, California), Neurophth, a fully integrated company, is striving to discover and develop genomic medicines for patients suffering from genetic diseases globally. Our validated AAV platform, which has been published in Nature - Scientific Reports, Ophthalmology, and EBioMedicine, has successfully delivered proof-of-concept investigator-initiated trials data of 198 subjects with investigational gene therapies in the retina. Our most advanced investigational candidate, NR082 (NFS-01 project, rAAV2-ND4), in development for the treatment ofND4-mediated LHON, has been granted orphan drug designation (ODD) by theU.S. FDA and its IND evaluating NR082 in a Phase 1/2/3 clinical trial has also been approved by the China NMPA in March 2021 with the first patient being dosed in June 2021. The pipeline also includesND1-mediated LHON, autosomal dominant optic atrophy, optic neuroprotection (e.g., glaucoma), vascular retinopathy (e.g., diabetic retinopathy), and five other preclinical candidates. Neurophth has initiated the scaling up in-house manufacturing process in single-use technologies to support future commercial demand at the Suzhou facilities. To learn more about us and our growing pipeline, visitwww.neurophth.com.

View original content to download multimedia:

SOURCE Neurophth Therapeutics, Inc.

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Read this article:
Qiutang Li, Neurophth CSO, Named Top 25 Women Leaders in Biotechnology 2021 - KWCH

Posted in Biotechnology | Comments Off on Qiutang Li, Neurophth CSO, Named Top 25 Women Leaders in Biotechnology 2021 – KWCH